Cardiac Transplantation

  • Donna M. Mancini


Since the first human heart transplantation in 1967 [1], cardiac transplantation has evolved from a medical curiosity to an accepted therapy for end-stage cardiomyopathy. Initial 1-year survival was only about 20%. With the general availability of cyclosporine in 1986, 1-year survival improved to more than 80%, with current 1-year survival now approaching 90% at high-volume transplant centers. Accordingly, the number of transplantations increased worldwide from 90 in 1981 to 2000 in 1988 to 3122 in 2001 [2].


Heart Transplantation Left Ventricular Assist Device Cardiac Transplantation Cardiac Allograft Vasculopathy Heart Lung Transplant 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Barnard CN: A human cardiac transplant: an interim report of a successful operation performed at Groote Schuur Hospital, Cape Town. S Afr Med J 1967, 41: 1271–1274.Google Scholar
  2. 2.
    Taylor D, Edwards L, Mohacsi P, et al.: The Registry of the International Society for Heart and Lung Transplantation: twentieth official adult heart transplant report 2003. J Heart Lung Transplant 2003, 22: 616–24.PubMedCrossRefGoogle Scholar
  3. 3.
    Gummert JF, Ikonen T, Morris RE: Newer immunosuppressive drugs: a review. J Am Soc Nephrol 1999, 10: 1366–1380.PubMedGoogle Scholar
  4. 4.
    Kobashigawa JA: Postoperative management following heart transplantation. Transplant Proc 1999, 31: 2038–2046.PubMedCrossRefGoogle Scholar
  5. 5.
    Young JB, Winters WL, Bourge R, Uretsky BF: 24th Bethesda Conference: Cardiac Transplantation. Task Force 4: Function of the Heart Transplant Recipient. J Am Coll Cardiol 1993, 22: 31–41.PubMedCrossRefGoogle Scholar
  6. 6.
    Evans RW, Manninen DL, Garrison LP Jr, Maier AM: Donor availability as the primary determinant of the future of heart transplantation. JAMA 1986, 255: 1892–1898.PubMedCrossRefGoogle Scholar
  7. 7.
    Goldstein D, Oz M, Rose E: Implantable left ventricular assist devices. N Engl J Med 1998, 339: 1522–1533.PubMedCrossRefGoogle Scholar
  8. 8.
    Rose E, Gelijns A, Moskovitz A, et al.: Long term use of a left ventricular assist device for end stage heart failure. N Engl J Med 2001, 345: 1435–1443PubMedCrossRefGoogle Scholar
  9. 9.
    Mancini DM, Eisen H, Kussmaul W, et al.: Value of peak exercise oxygen consumption for optimal timing of cardiac transplantation in ambulatory patients with heart failure. Circulation 1991, 83:778–786.PubMedCrossRefGoogle Scholar
  10. 10.
    Zugck C, Haunstetter A, Kruger C, et al.: Impact of beta blocker treatment on the prognostic value of currently used risk factors in congestive heart failure. J Am Coll Cardiol 2002, 39:1615–1622.PubMedCrossRefGoogle Scholar
  11. 11.
    Costanzo MR: Selection and treatment of candidates for heart transplantation: a statement for health professionals from the Committee on Heart Failure and Cardiac Transplantation of the Council on Clinical Cardiology, American Heart Association. Circulation 1995, 92: 3593–3612.PubMedCrossRefGoogle Scholar
  12. 12.
    Lurid L, Aaronson K, Mancini D: Predicting survival in ambulatory patients with severe heart failure on beta blocker therapy. Am J Cardiol, 2003, 92: 1350–1354.CrossRefGoogle Scholar
  13. 13.
    Aaronson KD, Schwartz JS, Chen TM, et al.: Development and prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac transplant evaluation. Circulation 1997, 95:2597–2599.CrossRefGoogle Scholar
  14. 14.
    Shumway NE, Lower RR, Stofer RC: Transplantation of the heart. Adv Surg 1966, 2: 265–284PubMedGoogle Scholar
  15. 15.
    Kawaguchi A, Gandjbakhch I, Pavie A, et al.: Factors affecting survival after heterotopic heart transplantation. J Thorac Cardiovasc Surg 1989, 98: 928–934.PubMedGoogle Scholar
  16. 16.
    Cooley DA: Techniques in Cardiac Surgery, edn 2. Philadelphia: WB Saunders; 1984: 372.Google Scholar
  17. 17.
    El Gamel A, Yonan NA, Grant S, et al.: Orthotopic cardiac transplantation: a comparison of standard and bicaval Wythenshawe techniques. J Thorac Cardiovasc Surg 1995, 109:721–730.CrossRefGoogle Scholar
  18. 18.
    Cerilli GJ: Organ Transplantation and Replacement. Philadelphia: JB Lippincott; 1988.Google Scholar
  19. 19.
    Unverferth DV: Dilated Cardiomyopathy. Mt. Kisco, NY: Futura Publishing Co; 1985.Google Scholar
  20. 20.
    Fishman J, Rubin R: Infection in organ transplant recipients. N Engl J Med 1998, 338: 1741–1751.PubMedCrossRefGoogle Scholar
  21. 21.
    Paris W, Woodbury A, Thompson S, et al.: Returning to work after heart transplantation. J Heart Lung Transplant 1993, 12: 46–54.PubMedGoogle Scholar
  22. 22.
    Beniaminovitz A, Coromilas J, Oz M, et al.: Electrical connection of native and transplanted sinus nodes via atrial pacing improves exercise performance after cardiac transplantation. Am J Cardiol 1998, 81:1373–1377.PubMedCrossRefGoogle Scholar
  23. 23.
    Michler RE, McLaughlin MJ, Chen JM, et al.: Clinical experience with cardiac retransplantation. J Thorac Cardiovasc Surg 1993, 106:622–629.PubMedGoogle Scholar
  24. 24.
    Ventura HO, Mehra MR, Smart FW, Stapleton DD: Cardiac allograft vasculopathy: current concepts. Am Heart J 1995, 129: 791–798.PubMedCrossRefGoogle Scholar
  25. 25.
    Costanzo-Nordin MR: Cardiac allograft vasculopathy: relationship with acute cellular rejection and histocompatibility. J Heart Lung Transplant 1992, 11 (suppl): 90–104.Google Scholar
  26. 26.
    Johnson MR: Transplant coronary artery disease: nonimmunologic risk factors. J Heart Lung Transplant 1992, 11 (suppl): 124–132.Google Scholar
  27. McDonald K, Rector TS, Braunlin EA, et al.: Association of coronary artery disease in transplant recipients with cytomegalovirus infection. Am J Cardiol 1989, 64:359–362.PubMedCrossRefGoogle Scholar
  28. 28.
    Mancini D, Pinney S, Burkhoff D, et al.: Use of rapamycin slows progression of cardiac transplant vasculopathy. Circulation 2003, 108:48–53.PubMedCrossRefGoogle Scholar
  29. 29.
    Eisen H, Dorent R, Kobashigawa J, et al.: Efficacy and safety of everolimus as part of a triple immunosuppressive regimen in de novo cardiac transplant recipients: 12 month results. N Engl J Med 2003, 349: 847–58.PubMedCrossRefGoogle Scholar
  30. 30.
    Helman D, Morales D, Edwards N, et al.: Left ventricular assist device bridge-to-transplant network improves survival after failed cardiotomy. Ann Thorac Surg 1999, 68:1187–1194.Google Scholar
  31. 31.
    Higgins RSD, Silverman NA: Status of permanent cardiac replacement for end-stage congestive heart failure. Heart Failure Reviews 1996, 1: 39–52.CrossRefGoogle Scholar
  32. 32.
    Kaplon R, Oz M, Kwiatowski K, et al: Miniature axial flow pump for ventricular assistance in children and small adults. J Thorac Cardiovasc Surg 1996, 111: 13–18.PubMedCrossRefGoogle Scholar
  33. 33.
    Sabbah H, Chaudhry P, Paone G, et al.: Passive ventricular constraint with the ACORN prosthetic jacket prevents progressive left ventricular dilation and improves ejection fraction in dogs with moderate heart failure. J Am Coll Cardiol 1999, 33: 207A.Google Scholar

Copyright information

© Springer Science+Business Media New York 2005

Authors and Affiliations

  • Donna M. Mancini

There are no affiliations available

Personalised recommendations